公开(公告)号：US20230365525A1

公开(公告)日：2023-11-16

申请号：US18139405

申请日：2023-04-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jianming Yu ,  Xiben Li ,  Robert Leon ,  Adam Szymaniak ,  In Jong Kim ,  Yat Sun Or

IPC: C07D401/12 ,  C07D417/12 ,  C07D401/14 ,  C07D413/14 ,  A61K45/06 ,  A61P31/14 ,  C07D471/04 ,  C07D417/14 ,  C07D409/14 ,  C07D405/14

CPC classification number: C07D401/12 ,  C07D417/12 ,  C07D401/14 ,  C07D413/14 ,  A61K45/06 ,  A61P31/14 ,  C07D471/04 ,  C07D417/14 ,  C07D409/14 ,  C07D405/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230115580A1

公开(公告)日：2023-04-13

申请号：US17720079

申请日：2022-04-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam Szymaniak ,  Jianming Yu ,  Kevin McGrath ,  Xiben Li ,  Tyler J. Mann ,  Robert Leon ,  In Jong Kim ,  Yat Sun Or ,  Long Nguyen

IPC: C07D491/048 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11534439B2

公开(公告)日：2022-12-27

申请号：US17368238

申请日：2021-07-06

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC: A61K31/498 ,  C07D491/107 ,  C07D519/00 ,  A61K45/06 ,  A61K31/4985 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11505558B1

公开(公告)日：2022-11-22

申请号：US17220300

申请日：2021-04-01

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam Szymaniak ,  Kevin McGrath ,  Jianming Yu ,  Tyler Mann ,  Long Nguyen ,  Kaicheng Zhu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D471/04 ,  C07D491/044 ,  C07D491/048 ,  C07D491/052

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220016112A1

公开(公告)日：2022-01-20

申请号：US17368238

申请日：2021-07-06

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC: A61K31/498 ,  C07D491/107 ,  C07D519/00 ,  A61K45/06 ,  A61K31/4985 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190040084A1

公开(公告)日：2019-02-07

申请号：US16100721

申请日：2018-08-10

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  Brian C. Shook ,  Thomas P. Blaisdell ,  In Jong Kim ,  Joseph Panarese ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Yat Sun Or

IPC: C07D519/00 ,  A61K31/554 ,  C07D491/048 ,  A61K31/551 ,  A61K45/06 ,  A61K31/55 ,  C07D495/04 ,  A61K31/553

CPC classification number: C07D519/00 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K45/06 ,  C07D401/06 ,  C07D401/14 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20180354912A1

公开(公告)日：2018-12-13

申请号：US16001247

申请日：2018-06-06

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Thomas P. Blaisdell ,  Brian C. Shook ,  In Jong Kim

IPC: C07D243/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20180193352A1

公开(公告)日：2018-07-12

申请号：US15863216

申请日：2018-01-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Jianming Yu ,  Thomas P. Blaisdell ,  Joseph Panarese ,  Yat Sun Or

IPC: A61K31/551 ,  A61P31/14 ,  C07D471/04 ,  C07D495/04

CPC classification number: A61K31/551 ,  A61P31/14 ,  C07D471/04 ,  C07D495/04

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.

公开(公告)号：US20170226129A1

公开(公告)日：2017-08-10

申请号：US15405526

申请日：2017-01-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  Brian C. Shook ,  Thomas P. Blaisdell ,  In Jong Kim ,  Joseph Panarese ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Yat Sun Or

IPC: C07D519/00 ,  A61K31/55 ,  A61K31/554 ,  A61K31/553 ,  A61K31/551 ,  C07D491/048 ,  C07D495/04 ,  A61K45/06

CPC classification number: C07D519/00 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K45/06 ,  C07D401/06 ,  C07D401/14 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US09669095B2

公开(公告)日：2017-06-06

申请号：US14931384

申请日：2015-11-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  In Jong Kim ,  Yat Sun Or

IPC: A61K38/13 ,  C07K7/64 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7056

CPC classification number: A61K45/06 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/21 ,  C07K7/645 ,  Y02A50/463 ,  A61K2300/00

Abstract: The present invention relates to novel cyclosporine analogs having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analog compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.